Mazalvix

Mesalazine, the active ingredient in Mazalvix, is a 5‑aminosalicylic acid (5‑ASA) presented as a rectal formulation for rectal use. It is employed to treat ulcerative colitis, particularly distal disease, by reducing inflammation of the colonic mucosa and helping maintain remission in affected patients.

GNH USA supplies Mazalvix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured distribution channels across Europe, Asia and the Americas. Our compliance with EU GMP standards ensures product consistency and safety for clinical use.

Mazalvix (mesalazine) acts locally in the colon to control inflammation associated with ulcerative colitis and related inflammatory bowel conditions.

Ulcerative colitis (distal disease): reduces mucosal inflammation and supports remission in patients with disease limited to the rectum and sigmoid colon. Inflammatory bowel disease (colonic involvement): helps control colonic inflammation when other therapies are insufficient. Proctitis: alleviates symptoms and promotes healing of rectal inflammation.

Mesalazine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Rectal irritation or burning sensation - Abdominal cramping or pain - Nausea or mild vomiting - Headache or dizziness

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis - Pancreatitis - Blood dyscrasias including neutropenia or agranulocytosis - Hepatotoxicity or liver enzyme elevation

Before initiating Mazalvix, clinicians should consider several precautionary measures to ensure safe use.

Renal function assessment: evaluate baseline kidney function and monitor periodically. Hepatic monitoring: check liver enzymes before treatment and during therapy. Hypersensitivity screening: avoid use in patients with known allergy to mesalazine or other 5‑ASA compounds. Concomitant NSAID use: exercise caution as combined therapy may increase renal toxicity. Pregnancy and lactation: safety data are limited; prescribe only if benefit outweighs potential risk. Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Mesalazine can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Warfarin: may increase anticoagulant effect and INR. - Azathioprine or 6‑mercaptopurine: risk of enhanced bone‑marrow suppression. - High‑dose oral corticosteroids: may increase risk of nephrotoxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: combined use can impair renal function. - Oral contraceptives: mesalazine may reduce hormonal efficacy. - Allopurinol: may raise mesalazine plasma levels. - Sulfasalazine: additive gastrointestinal irritation.